Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 77

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 77
---
's own data. Financial Assets and Liabilities Recorded at Fair ValueThe Company's financial assets and liabilities that are required to be measured at fair value on a recurring basis are as follows (dollars in thousands):Fair Value Measurements as of June 30, 2025 (unaudited) TotalLevel 1 Level 2Level 3Assets:Cash and cash equivalentsCash$53,557 $53,557 $— $— Money market funds91,154 91,154 — — Marketable securitiesCorporate debt securities367,895 — 367,895 — U.S government agency securities9,990 —9,990 —Other noncurrent assetsMarketable securities - restricted (SERP)660 24 636 — Total assets at fair value$523,256 $144,735 $378,521 $— Liabilities:Contingent consideration$— $— $— $— Total liabilities at fair value$— $— $— $— Fair Value Measurements as of December 31, 2024TotalLevel 1 Level 2Level 3Assets:Cash and cash equivalentsCash$37,830 $37,830 $— $— Money market funds31,501 31,501 — — Marketable securitiesCorporate debt securities355,201 — 355,201 — U.S. government agency debt securities29,080 —29,080 —Other noncurrent assetsMarketable securities - restricted (SERP)635 21 614 — Total assets at fair value$454,247 $69,352 $384,895 $— Liabilities:Contingent consideration$47,340 $— $— $47,340 Total liabilities at fair value$47,340 $— $— $47,340 

12

Other Financial Instruments

The carrying amounts of other financial instruments, including accounts receivable, accounts payable, and accrued expenses approximate fair value due to their short-term maturities. 

6. Contingent Consideration

The following table sets forth the contingent consideration for the USWM Acquisition and Adamas Acquisition (as defined below) (dollars in thousands):June 30, 2025December 31, 2024(unaudited)Reported under the following captions in the consolidated balance sheets: